The novel CRAFITY score—which takes into account C-reactive protein (CRP), alpha-foetoprotein (AFP), and immunotherapy—can be used to reliably assess survival and radiological response in hepatocellular carcinoma (HCC), a recent study has found. Future validation is needed before CRAFITY can be deployed to the clinics.
Exposure to environmental contaminants, particularly perfluorinated alkyl substances, seems to disrupt bile acid and lipid metabolism, both key hepatic metabolic pathways that are known to be dysregulated in nonalcoholic fatty liver disease (NAFLD), a recent study has found. Such an effect seems to be more pronounced in women.
Post hoc analyses evaluating adherence based on pill count in patients prescribed 8- or 12-week glecaprevir/pibrentasvir (G/P) reveal that treatment duration influences adherence rates and further stress the concept of “treatment forgiveness” with direct-acting antiviral therapies.
Endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous transhepatic biliary drainage (PTBD), either alone or in combination, are acceptable for the preoperative management of hilar cholangiocarcinoma (HC) and can help optimize patients for curative HC resection, a recent study has found.
Treatment with the novel, selective peroxisome proliferator-activated receptor α modulator (SPPARMα) pemafibrate appears to produce a significant reduction in liver stiffness but not in liver fat content in patients with high-risk nonalcoholic fatty liver disease (NAFLD), according to the results of a phase II trial.
Collagen proportionate area (CPA) is a good predictor of long-term mortality in alcoholic hepatitis (AH) patients regardless of their abstinence from alcohol, a recent study has found. However, CPA seems to have no clear interaction with short-term mortality.
Noninvasive markers, including alanine aminotransferase (ALT) and liver stiffness measurements (LSM), may help distinguish liver transplant (LT) recipients for whom minimizing immunosuppression would be safe, a recent study has found.
Nivolumab shows clinical activity in patients with advanced hepatocellular carcinoma (aHCC) with Child-Pugh B status, accompanied by a favourable safety profile and manageable side-effects, a recent study has found.